RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Abstracts of the 33rd Annual Meeting of the Italian Society of Uro-Oncology (SIUrO)
2023-01-01 Mollica, Veronica; Massari, Francesco; Rizzo, Mimma; Morelli, Franco; Grande, Enrique; Iacovelli, Roberto; Molina-Cerrillo, Javier; De Giorgi, Ugo; Fornarini, Giuseppe; Procopio, Giuseppe; Büchler, Tomáš; Cattrini, Carlo; Caffo, Orazio; Ortega, Cinzia; Soares, Andrey; Messina, Carlo; Monteiro, Fernando Sabino M.; Rizzo, Alessandro; Buti, Sebastiano; Porta, Camillo; Santoni 19 (on behalf of the ARON-1 Working Group), Matteo
Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial.
2023-01-01 Giannatempo, Patrizia; Guadalupi, Valentina; Marandino, Laura; Raggi, Daniele; Stellato, Marco; Rametta, Alessandro; Baciarello, Giulia; Bottiglieri, Achille; Sepe, Pierangela; Claps, Melanie; Buti, Sebastiano; Stefania, Pipitone; Iacovelli, Roberto; Calareso, Giuseppina; Alessi, Alessandra; Cattaneo, Laura; Verzoni, Elena; Procopio, Giuseppe; Mariani, Luigi; Necchi, Andrea
Adjuvant low-dose interleukin-2 (IL2) plus interferon-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the italian oncology group for clinical research (GOIRC)
2007-01-01 Passalacqua, R; Buzio, C; Potenzoni, D; Buti, S; Labianca, R; Porta, C; Nastasi, P; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Alberici, F; Bongiovanni, C; Pezzuolo, D; Caminiti, C
Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC)
2007-01-01 Passalacqua, R; Buzio, C; Buti, S; Labianca, R; Porta, C; Boni, C; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Caminiti, C
Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC) in metastatic renal cell cancer (mRCC): results and evaluation of circulating T-regulatory cells (Treg) and other cytokines. A GOIRC study
2010-01-01 Passalacqua, R; Buti, S; Simonelli, C; Rivoltini, L; Castelli, C; Camisaschi, C; Lo Re, G; Lleshi, A; Donnini, M; Lazzarelli, S
Bevacizumab (B) plus immunotherapy and chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial
2007-01-01 Buti, S; Brighenti, M; Dalla Chiesa, M; Simonelli, C; Passalacqua, R
Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC)
2008-01-01 Passalacqua, R; Buti, S; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Brighenti, M; Lazzarelli, S
Bevacizumab (B) plus low-doses immunotherapy (IT), plus chemotherapy (CT) (BIC), in metastatic renal cell cancer (mRCC): antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC)
2008-01-01 Buti, S; Lazzarelli, S; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Brighenti, M; Passalacqua, R
Bevacizumab plus immunotherapy, with interleukin-2 (IL-2) and interferone-alpha (IFN-alpha), plus chemotherapy (BIC), in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial
2007-01-01 Buti, S; Lazzarelli, S; Simonelli, C; Venturini, S; Spazzapan, S; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Brighenti, M; Mazza, G; Passalacqua, R
Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9)
2023-01-01 Basso, Umberto; Buti, Sebastiano; Verzoni, Elena; Sorarù, Mariella; Di Napoli, Marilena; Fratino, Lucia; Santini, Daniele; Grillone, Francesco; Chiuri, Vincenzo Emanuele Emanuele; Carella, Claudia; Atzori, Francesco; Roviello, Giandomenico; Sartori, Donata; Maruzzo, Marco; Pierantoni, Francesco; Bersanelli, Melissa; Ballestrin, Melissa; De Toni, Chiara; Mattana, Alvise; Zagonel, Vittorina
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Abstracts of the 33rd Annual Meeting of the Italian Society of Uro-Oncology (SIUrO) | 1-gen-2023 | Mollica, Veronica; Massari, Francesco; Rizzo, Mimma; Morelli, Franco; Grande, Enrique; Iacovelli, Roberto; Molina-Cerrillo, Javier; De Giorgi, Ugo; Fornarini, Giuseppe; Procopio, Giuseppe; Büchler, Tomáš; Cattrini, Carlo; Caffo, Orazio; Ortega, Cinzia; Soares, Andrey; Messina, Carlo; Monteiro, Fernando Sabino M.; Rizzo, Alessandro; Buti, Sebastiano; Porta, Camillo; Santoni 19 (on behalf of the ARON-1 Working Group), Matteo | |
| Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial. | 1-gen-2023 | Giannatempo, Patrizia; Guadalupi, Valentina; Marandino, Laura; Raggi, Daniele; Stellato, Marco; Rametta, Alessandro; Baciarello, Giulia; Bottiglieri, Achille; Sepe, Pierangela; Claps, Melanie; Buti, Sebastiano; Stefania, Pipitone; Iacovelli, Roberto; Calareso, Giuseppina; Alessi, Alessandra; Cattaneo, Laura; Verzoni, Elena; Procopio, Giuseppe; Mariani, Luigi; Necchi, Andrea | |
| Adjuvant low-dose interleukin-2 (IL2) plus interferon-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the italian oncology group for clinical research (GOIRC) | 1-gen-2007 | Passalacqua, R; Buzio, C; Potenzoni, D; Buti, S; Labianca, R; Porta, C; Nastasi, P; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Alberici, F; Bongiovanni, C; Pezzuolo, D; Caminiti, C | |
| Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC) | 1-gen-2007 | Passalacqua, R; Buzio, C; Buti, S; Labianca, R; Porta, C; Boni, C; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Caminiti, C | |
| Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC) in metastatic renal cell cancer (mRCC): results and evaluation of circulating T-regulatory cells (Treg) and other cytokines. A GOIRC study | 1-gen-2010 | Passalacqua, R; Buti, S; Simonelli, C; Rivoltini, L; Castelli, C; Camisaschi, C; Lo Re, G; Lleshi, A; Donnini, M; Lazzarelli, S | |
| Bevacizumab (B) plus immunotherapy and chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial | 1-gen-2007 | Buti, S; Brighenti, M; Dalla Chiesa, M; Simonelli, C; Passalacqua, R | |
| Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC) | 1-gen-2008 | Passalacqua, R; Buti, S; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Brighenti, M; Lazzarelli, S | |
| Bevacizumab (B) plus low-doses immunotherapy (IT), plus chemotherapy (CT) (BIC), in metastatic renal cell cancer (mRCC): antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC) | 1-gen-2008 | Buti, S; Lazzarelli, S; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Brighenti, M; Passalacqua, R | |
| Bevacizumab plus immunotherapy, with interleukin-2 (IL-2) and interferone-alpha (IFN-alpha), plus chemotherapy (BIC), in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial | 1-gen-2007 | Buti, S; Lazzarelli, S; Simonelli, C; Venturini, S; Spazzapan, S; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Brighenti, M; Mazza, G; Passalacqua, R | |
| Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9) | 1-gen-2023 | Basso, Umberto; Buti, Sebastiano; Verzoni, Elena; Sorarù, Mariella; Di Napoli, Marilena; Fratino, Lucia; Santini, Daniele; Grillone, Francesco; Chiuri, Vincenzo Emanuele Emanuele; Carella, Claudia; Atzori, Francesco; Roviello, Giandomenico; Sartori, Donata; Maruzzo, Marco; Pierantoni, Francesco; Bersanelli, Melissa; Ballestrin, Melissa; De Toni, Chiara; Mattana, Alvise; Zagonel, Vittorina |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Articolo su rivista 113
- 1 Articolo su rivista::1.5 Abstra... 113
Data di pubblicazione
- 2020 - 2023 38
- 2010 - 2019 45
- 2004 - 2009 30
Editore
- ASCO pubs 11
- Elsevier 6
- SAGE PUBLICATIONS LTD 5
- ELSEVIER 4
- BioMed Central 2
- International Institute of Antica... 1
- LIPPINCOTT WILLIAMS & WILKINS 1
- SAGE 1
Rivista
- ANNALS OF ONCOLOGY 39
- JOURNAL OF CLINICAL ONCOLOGY 39
- TUMORI 8
- I SUPPLEMENTI DI TUMORI 5
- JOURNAL OF THORACIC ONCOLOGY 4
- JOURNAL OF CLINICAL ONCOLOGY 3
- ANTICANCER RESEARCH 2
- GIORNALE ITALIANO DI NEFROLOGIA 2
- JOURNAL FOR IMMUNOTHERAPY OF CANCER 2
- ANTICANCER RESEARCH 1
Keyword
- Poster presentation at AIOM 2022 1
Lingua
- eng 95
- ita 4
- fre 1
Accesso al fulltext
- no fulltext 110
- open 3